Dechra Pharmaceuticals (LON:DPH – Get Rating) had its target price trimmed by JPMorgan Chase & Co. from GBX 4,600 ($55.32) to GBX 4,000 ($48.10) in a research note released on Tuesday morning, MarketBeat.com reports. The firm currently has an overweight rating on the stock.
Other equities research analysts also recently issued reports about the stock. Berenberg Bank reissued a hold rating and issued a GBX 2,850 ($34.27) price objective on shares of Dechra Pharmaceuticals in a research report on Monday, February 27th. Jefferies Financial Group reaffirmed a buy rating and issued a GBX 3,112 ($37.42) target price on shares of Dechra Pharmaceuticals in a report on Tuesday, February 28th.
Dechra Pharmaceuticals Stock Down 1.6 %
Shares of LON DPH opened at GBX 2,728.68 ($32.81) on Tuesday. Dechra Pharmaceuticals has a 1 year low of GBX 2,487.45 ($29.91) and a 1 year high of GBX 4,310 ($51.83). The company has a debt-to-equity ratio of 49.35, a current ratio of 2.80 and a quick ratio of 1.66. The company has a market capitalization of £3.11 billion, a P/E ratio of 5,230.19, a P/E/G ratio of 1.42 and a beta of 0.68. The company has a 50 day simple moving average of GBX 2,869.45 and a 200-day simple moving average of GBX 2,844.25.
Dechra Pharmaceuticals Cuts Dividend
About Dechra Pharmaceuticals
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies.
- Under-the-Radar Azul SA Takes Flight on Robust Travel Demand
- Market Gets “Powelled”: S&P 500 Confirms Resistance
- Rivian Plummets, But Is This 2023’s Greatest Buying Opportunity?
- Ulta Insiders Hold Tight: Sell-Siders Buy
- Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Receive News & Ratings for Dechra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.